Payment overview · 2025
General Payments
$379.88
21 reported records · 7 companies
Healthcare provider profile · identity verified
Steven L. Douglas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EAST PRAIRIE, MO · NPI 1497733893
Verified facts
What the public records show
CMS Open Payments records show Steven L. Douglas, M.D. received $379.88 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.90 | 38.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.76 | 17.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.60 | 14.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.55 | 13.6% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.35 | 5.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.04 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.68 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.88 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.03 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.76 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.60 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 325 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
325 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1121 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 937 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 894 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 880 | 169 |
| Lisinopril | Lisinopril | 735 | 128 |
| Gabapentin | Gabapentin | 715 | 114 |
| Furosemide | Furosemide | 612 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 598 | 103 |
| Omeprazole | Omeprazole | 582 | 92 |
| Alprazolam | Alprazolam | 497 | 65 |
| Tramadol Hcl | Tramadol Hcl | 449 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 412 | 68 |
| Losartan Potassium | Losartan Potassium | 410 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 72 |
| Montelukast Sodium | Montelukast Sodium | 401 | 56 |
| Metformin Hcl | Metformin Hcl | 388 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 385 | 62 |
| Carvedilol | Carvedilol | 337 | 56 |
| Ozempic | Semaglutide | 325 | 48 |
| Trazodone Hcl | Trazodone Hcl | 318 | 59 |
| Potassium Chloride | Potassium Chloride | 311 | 42 |
| Pregabalin | Pregabalin | 308 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 303 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 277 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 263 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 36 |
| Buspirone Hcl | Buspirone Hcl | 258 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 251 | 33 |
| Farxiga | Dapagliflozin Propanediol | 244 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 47 |
| Eliquis | Apixaban | 225 | 31 |
| Meloxicam | Meloxicam | 225 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 211 | 21 |
| Mirtazapine | Mirtazapine | 209 | 34 |
| Clonazepam | Clonazepam | 196 | 31 |
| Ezetimibe | Ezetimibe | 195 | 32 |
| Mounjaro | Tirzepatide | 185 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 30 |
| Celecoxib | Celecoxib | 171 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 168 | 21 |
| Jardiance | Empagliflozin | 163 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 162 | 26 |
| Glimepiride | Glimepiride | 159 | 28 |
| Topiramate | Topiramate | 155 | 21 |
| Spironolactone | Spironolactone | 153 | 21 |
| Lorazepam | Lorazepam | 150 | 20 |
| Sertraline Hcl | Sertraline Hcl | 144 | 27 |
| Bupropion Xl | Bupropion Hcl | 141 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 23 |
| Prednisone | Prednisone | 128 | 70 |
| Repatha Sureclick | Evolocumab | 128 | 17 |
| Sucralfate | Sucralfate | 128 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 121 | 24 |
| Allopurinol | Allopurinol | 119 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 25 |
| Clonidine Hcl | Clonidine Hcl | 115 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 112 | 19 |
| Torsemide | Torsemide | 112 | 17 |
| Doxepin Hcl | Doxepin Hcl | 110 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 73 |
| Naproxen | Naproxen | 106 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 98 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 15 |
| Diazepam | Diazepam | 95 | 18 |
| Baclofen | Baclofen | 93 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 93 | 21 |
| Januvia | Sitagliptin Phosphate | 93 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 19 |
| Chlorthalidone | Chlorthalidone | 90 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 85 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 15 |
| Finasteride | Finasteride | 81 | 15 |
| Myrbetriq | Mirabegron | 80 | suppressed |
| Memantine Hcl | Memantine Hcl | 79 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 27 |
| Trulicity | Dulaglutide | 76 | 15 |
| Nystatin | Nystatin | 71 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 12 |
| Methocarbamol | Methocarbamol | 67 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 29 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Linzess | Linaclotide | 61 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Belsomra | Suvorexant | 60 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 60 | suppressed |
| Glipizide | Glipizide | 60 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | 14 |
| Lubiprostone | Lubiprostone | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 27 |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 57 | 13 |
| Promethazine Hcl | Promethazine Hcl | 57 | 13 |
| Vascepa | Icosapent Ethyl | 56 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Eszopiclone | Eszopiclone | 55 | suppressed |
| Lovastatin | Lovastatin | 55 | 11 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Estradiol | Estradiol | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Ramipril | Ramipril | 49 | suppressed |
| Ibuprofen | Ibuprofen | 48 | suppressed |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Lactulose | Lactulose | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 16 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 32 |
| Famotidine | Famotidine | 37 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 19 |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Constulose | Lactulose | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Brilinta | Ticagrelor | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.88 · 21 records | ABBVIE INC. | Auvelity, Dexcom G6 Transmitter, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Tymlos, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error